US Wound Biologics Market - Focused Insights 2023-2028

This report offers market size & forecast data for the wound biologics market in the US. The revenue generated from product offerings is included in the report. This report provides a comprehensive and current market scenario of the US wound biologics market, including the US wound biologics market size, anticipated market forecast, relevant market segmentations, and industry trends.

The study considers a detailed scenario of the present wound biologics market and its market dynamics for 2023-2028 in the US. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent players operating in the market.

MARKET DEFINITIONWound Biologics are the treatment products from living organisms or cells. Biologic wound healing therapies are intended to facilitate the re-establishment of innate repair mechanisms and may involve the application of active biological agents.

KEY HIGHLIGHTS- In the US, the wound biologics market was valued at $630.00 million in 2022 and is expected to reach $1,214.92 million with a CAGR of 11.57% during the forecast period.
- In the US, the wound biologics market is growing with an absolute growth of 92.84% and incremental growth of $584.92 million during the forecast period. The market is growing due to the rising prevalence of acute and chronic wounds, majorly due to diabetes, surgical wounds, burns, and trauma, as well as the high adoption of advanced wound biologic products.
- In 2022, Biological Skin Substitutes dominated the product segment with 61.45% market share and are expected to grow at a CAGR of 11.29% during the forecast period. This is due to increasing demand for advanced biological skin substitutes as the chances of incidence of chronic wounds are rising at a higher rate in the growing population.
- In 2022, Specialty wound care clinics showed dominance over others with a 65.87% market share and are expected to grow at a CAGR of 11.91% during the forecast period. This dominance is due to the high number of wound care specialty clinics across the US.
- In 2022, the chronic wounds segment accounted for the market share of 52.54% and is expected to grow at a CAGR of 12.08% during the forecast period. The rise in the incidence of diabetes & obesity and the rise in the geriatric population are key factors contributing to the rising number of chronic wound cases in the US.
- Avita Medical, Organogenesis, Smith+Nephew, Vericel, and Orthofix dominate the US wound biologics market. The major players focus on strategic acquisitions and collaborations with emerging players to enter the wound biologics market and gain access to commercially launched products.

VENDORS LIST- Avita Medical
- Organogenesis
- Smith+Nephew
- Vericel Corporation
- Orthofix
- Bioventus
- Cytori
- Ethicon
- Integra LifeSciences
- Marine Polymer Technologies
- Medline Industries
- MiMedx
- Molnlycke
- Nuo Therapeutics
- Skye Biologics
- Stability Biologics
- Stryker
- Surgilogix
- Tides Medical
- Viscus Biologics
- BD
- Convatec
- Regen Lab
- PRP Concepts
- Anika Therapeutics
- AlloSource
- Amino Technology

PRODUCT SEGMENTATION & FORECASTBy product
- Biological Skin Substitutes- Growth Factors
By wound type
- Chronic wounds- Acute wounds
- End-user
- Specialty wound care clinics
- Hospitals
- Long-term care centers

MARKET STRUCTURE- Market Dynamics
- Competitive Landscape of Wound Biologics Market
- Key Vendors
- Other Prominent Vendors

APPENDIX- Research Methodology
- Abbreviations
- About the Analyst